Occuity Ltd of Reading at MEDICA 2021 in Düsseldorf -- COMPAMED Trade Fair
Manage stand orders
Select Option

Occuity Ltd

The Blade Abbey Square, RG13BE Reading
United Kingdom of Great Britain and Northern Ireland
Telephone +44 1183 500800

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Hall map

MEDICA 2021 hall map (Hall 16): stand J42

Fairground map

MEDICA 2021 fairground map: Hall 16

Our range of products

Product categories

  • 01  Imaging and diagnostics / medical equipment and devices
  • 01.01  Diagnostics
  • 01.01.02  Instruments and apparatus for ocular diagnosis

Our products

Product category: Instruments and apparatus for ocular diagnosis

PM1 Pachymeter

The first of Occuity's revolutionary optical handheld devices, the PM1 Pachymeter offers many advantages over existing ultrasound technology and allows for a non-clinical operator to take a corneal centre thickness measurement quickly and easily.

More Less

Product category: Instruments and apparatus for ocular diagnosis

PM1 MultiMeter

Following on from the PM1 and AX1, Occuity will look to add additional functionality to our technology platform. The PM2 will provide pachymetry alongside additional measurement sets which is likely to include pupillometry and keratometry. 

More Less

Product category: Instruments and apparatus for ocular diagnosis

AX1 - Axial Length Biometer

The AX1 will build upon the novel optical technology utilised within the PM1 to enable direct axial length measurement - all within a compact handheld device. Utilising a similar form factor to the PM1 will help Occuity accelerate the development of the AX1.

More Less

Product category: Instruments and apparatus for ocular diagnosis

Disease Screening - Diabetes and Alzheimer's Disease

Non-contact diagnostics through the eye.

Building upon our patented technology, Occuity's disease screening products, will seek to make it easier and cheaper to screen for chronic diseases such as diabetes and Alzheimer's in non-clinical settings such as high street pharmacies and care homes.

More Less

Product category: Instruments and apparatus for ocular diagnosis

Non-invasive Glucose Monitoring - Occuity Indigo

Occuity is researching and developing novel handheld devices to monitor disease progression through subtle changes within the eye. Occuity has developed novel confocal scanning technology, protected by 9 international patents to allow for the measurement of a suite of parameters through the eye that can be used for accurate measurement of both the physiological and chemical changes that are associated with disease progression.

Instead of relying on finger-prick blood tests to provide blood glucose readings, Occuity is in the process of developing a non-contact handheld optical device to determine the blood glucose level by measuring subtle changes within the anterior chamber of the eye. There are numerous medical papers that support the direct correlation of changes within the anterior chamber with fluctuations in blood glucose. The glucose monitor under development by Occuity builds on this correlation.

More Less

Company news

Date

Topic

11 Nov 2021

UK MedTech firm, Occuity, to showcase first device at MEDICA 2021 after successfully raising over £2m

UK MedTech firm, Occuity, successfully raises over £2m to deliver ophthalmic and optical diabetes devices. Occuity have also announced they will be exhibiting on the ABHI UK Pavilion at MEDICA 2021, Düsseldorf, the world’s no. 1 medical trade fair, giving buyers the exclusive opportunity to be the first to get hands-on with the world’s first handheld, non-contact, optical pachymeter - the Occuity PM1.

  • Occuity to launch pioneering ophthalmic pachymeter, the Occuity PM1, at MEDICA 2021. Based on Occuity’s multi-patented precision optical systems technology, the PM1 can measure corneal thickness in just a few seconds and will be the first of a series of ophthalmic devices from the company.
  • Successful £2m investment round will help accelerate development of non-invasive diabetes detection and personal management devices by the end of 2025
  • Former Apple design director Daniele De Iuliis part of an expert team developing new B2B and consumer optical Medtech devices
Occuity, a UK-based medical technology start-up, is celebrating after successfully hitting their £1.8m investment target just 24 hours after their launch on leading crowdfunding platform, Seedrs. With the round still open, the company now plan to ‘overfund’ to allow them to accelerate the development of their innovative optical devices.

CEO and Co-founder Dr. Dan Daly comments: We’re delighted with the level of interest we have received during this finance round and thrilled that we are now overfunding. To date, we have now raised over £2m which will allow us to accelerate the development of our new optical screening and monitoring devices that aim to detect the early signs of chronic health conditions by scanning the human eye.”

Founded in 2019, Occuity has developed and patented its contactless optical technology to obtain precise measurements from the eye. Occuity’s vision is to use the eye as a window into the health of the body and to utilise their non-invasive, non-contact handheld technology to bring a range of new medical devices to market which uses this technology for ophthalmic examinations, diabetes management, pre-diabetes screening and, in the longer term, the early detection of Alzheimer’s disease.

Dr Dan Daly continued: “We are developing game-changing medical devices for use in non-clinical settings and by the patient. Thanks to our technology, all of our devices will be optical, handheld and non-contacting, which of course offers many benefits.”

“We have a roadmap of products starting with our ophthalmic series and moving on to screening and monitoring devices for diabetes and eventually other chronic conditions such as Alzheimer’s.

“We’re looking forward to showcasing our first device, the PM1 pachymeter, at MEDICA and talking to buyers about our technology the other devices in our product pipeline.”

The roll-out plan for Occuity’s new medical devices includes:

  • Occuity’s first device, the PM1 Pachymeter is aimed at the optometry market and measures corneal thickness with micrometre level precision. This is due to begin clinical testing and is expected to be approved for use in the EU by early 2022. Planned follow up devices will include measurements such as axial length, keratometry and pupillometry
  • The company plans to launch a pre-diabetes screening device in 2024 to allow mass testing for the emerging signs of Type 2 diabetes at pharmacies and opticians.
  • In 2025, it intends to introduce a personal non-invasive optical glucose monitor that will enable people with diabetes to monitor their blood-sugar levels without drawing blood
  • Occuity hopes that its research and development will also support the delivery of a routine screening device capable of detecting early signs of Alzheimer’s disease by identifying biomarkers deposited in the eye.

Design Director, Daniele De Iuliis, comments: “The work we are doing at Occuity is hugely exciting with the opportunity to deliver a step-change over the next decade in optometry practice and the way chronic diseases like diabetes and Alzheimer’s are detected and managed.

“Thanks to Occuity’s ingenuity, it is becoming possible to detect and manage debilitating health conditions through a quick, non-contact eye scan.”

“It’s important to all of us that the devices we’re developing will be kinder, more intuitive and more convenient than existing technologies, and they will be accessible to all.”

For more information please contact:

Richard Kadri-Langford

Head of Digital Marketing
www.occuity.com
richard.kadri-langford@occuity.com 
Tel: 01183 500 800


Notes to editors:

·        Meta-analysis of data from 50 studies estimates the number of people (aged 40-80 years) with glaucoma worldwide was 64.3 million in 2013. This number is expected to reach 76 million in 2020 and 111.8 million by 2040. (Source: Ophthalmology, 2014)

·        The number of people with diabetes rose from 108 million in 1980 to 422 million in 2014, with diabetes prevalence rising more rapidly in low- and middle-income countries. An estimated 1.6 million deaths were directly caused by diabetes in 2016. (Source: World Health Organisation, 2020)

·        Around 50 million people worldwide have dementia, and there are nearly 10 million new cases every year. Alzheimer's disease is the most common form of dementia and may contribute to 60–70% of cases. (Source: World Health Organisation, 2020)


About Occuity: www.occuity.com

Founded in 2019, Occuity is a UK-based medical technology company specialising in the research, design and production of non-contacting optical instruments for healthcare diagnostics and monitoring. Occuity’s scanning technology uses light to obtain accurate and precise measurements from the eye and is protected by nine granted patents and a further five patent applications.

Occuity's Intellectual Property includes 9 granted international patents covering the measurement technique and optical technology that forms the basis of the devices along with additional patents relating to the alignment and measurements within the eye.

Occuity's mission is to create a range of non-contact, handheld devices which by their nature will be useable in a non-clinical setting by healthcare professionals and personal monitoring devices for diseases such as diabetes.

More Less

About us

Company portrait

Thank you for your interest in Occuity. 

Founded in 2019, Occuity is a UK-based medical technology company specialising in the research, design, and production of handheld non-contacting optical instruments for use in healthcare, diagnostics, and monitoring. Occuity’s scanning technology uses light to obtain precise measurements of different structures within the eye. This enables direct measurements of the eye for optometrists and ophthalmologists but also, other more general health conditions such as diabetes and Alzheimer’s Disease to be monitored.

Occuity's Intellectual Property includes nine granted international patents with a further five patent applications covering the measurement technique and optical technology that forms the basis of the devices along with additional patents relating to the alignment and measurements within the eye.
 
Occuity's mission is to create a range of non-contact, handheld devices which by their nature will be useable in a non-clinical setting by healthcare professionals and personal monitoring devices for diseases such as diabetes.

Company data

Number of employees 20-49
Foundation 1999
Area of business Imaging and diagnostics / medical equipment and devices